The Virility Paradox: The Vast Influence of Testosterone on Our Bodies, Minds, and the World We Live In - Tapa dura

Dr. Ryan is internationally known for clinical research in castration resistant prostate cancer (CRPC), with over 100 scientific publications Dr. Ryan has lectured at top universities (including Harvard and Stanford) and internationally Hudson Perigo has collaborated with physicians, educators, scientists, and business leaders on more than 30 books Author connections to many promotional outlets, including "Doctor Radio" on Sirius XM, Men's Health Magazine, The Guardian, The Strand Bookstore, Movember, KQED (San Francisco NPR station), and more. Dr. Ryan has created online continuing education videos through UroToday.com that have been viewed over 68K times and the CEO of Urotoday has offered free advertisement of the book Plans to hire outside publicist

Charles J Ryan, MD, is The Thomas Perkins Distinguished Professor of Clinical Medicine and Urology at the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF). Dr. Ryan earned a BA in Philosophy, magna cum laude from Marquette University where he was inducted into Phi Beta Kappa. He attended the University of Wisconsin Medical School. He trained at the University of Wisconsin Hospital and at Memorial Sloan-Kettering Cancer Center in New York. He is the Program Leader for genitourinary medical oncology at UCSF and is Chair of the UCSF Committee on Human Research, which oversees the ethical conduct of research on humans at the institution. He serves as co-chair of the National Cancer Institute's Prostate Cancer Task Force and the leader of the Advanced Prostate Cancer Cadre in the Alliance for Clinical Trials in Oncology, a national clinical trials group. Dr. Ryan's research focuses on the development of new treatments for advanced prostate cancer and he has published over 100 articles and chapters in the world's leading medical journals including the New England Journal of Medicine. In addition, he was the principal investigator for the development of Abiraterone acetate, a treatment now considered a standard of care in advanced prostate cancer. It has been administered to over 200,000 patients worldwide. Dr. Ryan is the cofounder of the Supportive Therapy in Androgen Deprivation (STAND) program at UCSF, a program which seeks to integrate physical activity, nutrition, and emotional support for men receiving hormonal therapy for prostate cancer and their partners.